247 related articles for article (PubMed ID: 30297432)
21. Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Ingram JR; Blomberg OS; Rashidian M; Ali L; Garforth S; Fedorov E; Fedorov AA; Bonanno JB; Le Gall C; Crowley S; Espinosa C; Biary T; Keliher EJ; Weissleder R; Almo SC; Dougan SK; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3912-3917. PubMed ID: 29581255
[TBL] [Abstract][Full Text] [Related]
22. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
23. TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy.
Stone ML; Lee J; Herrera VM; Graham K; Lee JW; Huffman A; Coho H; Tooker E; Myers MI; Giannone M; Li Y; Buckingham TH; Long KB; Beatty GL
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34101617
[TBL] [Abstract][Full Text] [Related]
24. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
25. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X; Chan HTC; Fisher H; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; French RR; Duriez PJ; Douglas LR; English V; Verbeek JS; White AL; Tews I; Glennie MJ; Cragg MS
Cancer Cell; 2020 Jun; 37(6):850-866.e7. PubMed ID: 32442402
[TBL] [Abstract][Full Text] [Related]
26. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
27. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
[TBL] [Abstract][Full Text] [Related]
28. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
29. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Sum E; Rapp M; Fröbel P; Le Clech M; Dürr H; Giusti AM; Perro M; Speziale D; Kunz L; Menietti E; Brünker P; Hopfer U; Lechmann M; Sobieniecki A; Appelt B; Adelfio R; Nicolini V; Freimoser-Grundschober A; Jordaan W; Labiano S; Weber F; Emrich T; Christen F; Essig B; Romero P; Trumpfheller C; Umaña P
Clin Cancer Res; 2021 Jul; 27(14):4036-4053. PubMed ID: 33771854
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
32. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
33. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
35. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
36. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
[TBL] [Abstract][Full Text] [Related]
37. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Kosaka A; Ohkuri T; Okada H
Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
[TBL] [Abstract][Full Text] [Related]
38. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
39. Expression and functional role of co-stimulatory molecules in CD40+IL-4-stimulated B cells from atopic and non-atopic donors.
Oberwalleney G; Henz BM; Worm M
Acta Derm Venereol; 2000; 80(4):287-91. PubMed ID: 11028864
[TBL] [Abstract][Full Text] [Related]
40. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.
Kwong B; Liu H; Irvine DJ
Biomaterials; 2011 Aug; 32(22):5134-47. PubMed ID: 21514665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]